Show simple item record

AuthorChemaitelly, Hiam
AuthorAyoub, Houssein H.
AuthorCoyle, Peter
AuthorTang, Patrick
AuthorYassine, Hadi M.
AuthorAl Thani, Asmaa A.
AuthorAl-Khatib, Hebah A.
AuthorHasan, Mohammad R.
AuthorAl-Kanaani, Zaina
AuthorAl-Kuwari, Einas
AuthorJeremijenko, Andrew
AuthorKaleeckal, Anvar Hassan
AuthorLatif, Ali Nizar
AuthorShaik, Riyazuddin Mohammad
AuthorAbdul-Rahim, Hanan F.
AuthorNasrallah, Gheyath K.
AuthorAl-Kuwari, Mohamed Ghaith
AuthorAl-Romaihi, Hamad Eid
AuthorButt, Adeel A.
AuthorAl-Thani, Mohamed H.
AuthorAl-Khal, Abdullatif
AuthorBertollini, Roberto
AuthorAbu-Raddad, Laith J.
Available date2023-03-28T07:44:50Z
Publication Date2023-03-01
Publication NameThe Lancet Infectious Diseases
Identifierhttp://dx.doi.org/10.1016/S1473-3099(23)00005-1
CitationChemaitelly H, Ayoub HH, Coyle P, Tang P, Yassine HM, Al Thani AA, Al-Khatib HA, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Al-Romaihi HE, Butt AA, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents. Lancet Infect Dis. 2023 Mar;23(3):276-277. doi: 10.1016/S1473-3099(23)00005-1.
ISSN14733099
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85148707656&origin=inward
URIhttp://hdl.handle.net/10576/41365
AbstractCOVID-19 vaccine antigen dose might affect protection against SARS-CoV-2 infection,1, 2 but direct evidence to quantify this effect is absent. We conducted a matched, retrospective, cohort study using a regression discontinuity design3 to emulate a randomised controlled trial in Qatar between Feb 3, 2022, and Nov 8, 2022, to provide a head-to-head, controlled comparison of protection induced by two different antigen doses of the BNT162b2 (Pfizer–BioNTech) vaccine (appendix pp 4–10). The study compared incidence of infection with the omicron (B.1.1.529) variant in the national cohort of adolescents aged 12 years who received the two-dose 30 μg BNT162b2 primary series with that in the national cohort of adolescents aged 11 years who received the two-dose pediatric 10 μg BNT162b2 primary series.
Languageen
PublisherElsevier
SubjectCOVID-19
SARS-CoV-2
omicron infection
TitleBNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
TypeOther
Pagination276-277
Issue Number3
Volume Number23
ESSN1474-4457
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record